Impact of Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: ROSSINI Study Insights

The interim findings from the ROSSINI study highlight the significant benefits of foslevodopa/foscarbidopa (LDp/CDp) in treating advanced Parkinson's disease over a six-month period. The study, which included 105 participants, demonstrated that LDp/CDp notably decreased OFF time by 2.7 hours and dyskinesia time by 1.7 hours, alongside improvements in various quality-of-life metrics such as sleep and pain scales.

Conducted as a multicountry, observational study, ROSSINI assesses the therapy's efficacy and safety in real-world settings. The safety profile was deemed acceptable, with most adverse events being mild to moderate. Remarkably, LDp/CDp has become the first FDA-approved subcutaneous levodopa infusion for advanced Parkinson's. Overall, the results underscore the potential of LDp/CDp to enhance the quality of life for patients experiencing motor fluctuations in advanced stages of the disease.